DIAGNOSING ALZHEIMER’S DISEASE IN THE BLINK OF AN EYE

A Simple Eye Scan to Detect a
Key Biomarker of Alzheimer’s Disease.
This can change everything.

We have a vision

By 2050, the number of people suffering from Alzheimer’s disease will have tripled, affecting a projected 13.8 million people in the US alone. Early detection of this horrible disease is crucial. We’re focused on a solution.

About us

Innovation

Our team is developing a ground-breaking tool for identifying beta-amyloid (AB) plaques, a key biomarker of this disease.

Technologies

1 out of 9 people
over the age of 65 suffers
from Alzheimer’s

Alzheimer’s is a leading cause for disability and dependency in later life. We’re working towards changing this.

Patients

Our experts

Optina Diagnostics is made up of a driven and dynamic team of experts in the areas of business development, research, and finance.
Team

David Lapointe, M. Sc.

President and CEO

Chantal Miklosi

CFO

Jean-Philippe Sylvestre, ing., M.Sc., Ph.D.

CTO

Claudia Chevrefils, ing., Ph.D.

CIO

Marie-Andrée Tremblay, ing.

Scientific Team

Anne-Marie Bédard

Clinical Study Manager

Sébastien Blais Ouellette, Ph.D.

Board of Directors

Jean Daniel Arbour

Board of Directors